Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YF087 in MSI-H or dMMR Advanced Solid Tumors
NCT07809607Phase 1Not yet recruiting
- Sponsor
- InventisBio
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
Phase 1, open-label, single-arm trial of YF087 in solid tumor, sponsored by InventisBio. Primary endpoints: Number of subjects participants with adverse events, Subject incidence of Dose-limiting toxicities and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
YF087
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07809607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809607.